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Background: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM)
are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of
saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs
(OADs) and identified factors associated with saxagliptin use.
Methods: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health
Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRDSM) across the first
36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old,
2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days.
For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex,
and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use.
Results: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRDSM: 8,057) and
610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRDSM: 77,808). Across
all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin
initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of
hemoglobin A1c measurements in the US data sources.
Conclusions: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control,
prior OAD use, and diagnoses of hypertension and hyperlipidemia.
Trial registration: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and
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Type 2 diabetes mellitus (T2DM) is a global public health
problem, affecting 347 million people worldwide [1,2].
Current estimates suggest that more than 29.1 million
adults and children in the United States (US) and 3.2
million adults and children in the United Kingdom (UK)
have T2DM, representing more than 9.3% and 6% of these
populations, respectively [3-5]. Oral anti-diabetic drugs
(OADs), along with diet and exercise, can help to control
T2DM-associated hyperglycemia in adults [6].
Saxagliptin, a relatively new dipeptidyl peptidase-4
(DPP-4) inhibitor [7], was approved by the US Food
and Drug Administration (FDA) in July 2009 and the
European Medicines Agency in October 2009 to be
used with diet and exercise to control hyperglycemia
in adults with T2DM. In clinical trials, saxagliptin
was shown to be efficacious in lowering fasting
plasma glucose, 2-hour postprandial glucose, and
hemoglobin A1c when used as monotherapy [8], in
combination with metformin in treatment-naive patients
[9], or as add-on therapy to metformin [10], sulfonylureas
[11], thiazolidinediones [12], or insulin [13]. Because
of its recent market introduction, prescribing patterns
associated with saxagliptin’s use in real-world settings
remain unknown. Determining how OADs are prescribed
in clinical practice can provide valuable information on
healthcare decision-making [14,15]. Further, since the
effectiveness and safety of saxagliptin and other OAD
therapies may be affected by demographic characteristics,
medical comorbidities, and additional medications pre-
scribed to T2DM patients, identifying the factors associ-
ated with the use of particular OADs in real-world settings
can provide important information needed for the future
conduct of studies evaluating the comparative effectiveness
and safety of anti-diabetic drugs. In particular, such
variables can be incorporated within propensity scores to
help to minimize confounding by indication [16,17].
The objectives of this study were to: 1) compare the
characteristics of patients with T2DM who newly initiate
saxagliptin to those who newly initiate OADs in classes
other than DPP-4 inhibitors, and 2) identify determinants
of saxagliptin use during the first years of its availability in
the UK and US. We hypothesized that T2DM patients with
poor glycemic control, a higher prevalence of microvascu-
lar and macrovascular complications, and prior OAD use
would be more likely to initiate saxagliptin.
Methods
Data sources
Four data sources, two each in the UK and US, were
used in this study. Within the UK, data from the Clinical
Practice Research Datalink (CPRD; formerly General
Practice Research Database) and The Health Improvement
Network (THIN) were evaluated over the first 36 monthsof saxagliptin availability (5 October 2009 to 30 September
2012). Within the US, data from US Medicare were
evaluated across all 50 states over the first 29 months of
saxagliptin availability (1 August 2009 to 31 December
2011), due to the lag in availability of these data. The
HealthCore Integrated Research Database (HIRDSM) data
were examined over the first 36 months of saxagliptin
availability (1 August 2009 to 31 July 2012). These four
databases were selected because they include large
numbers of T2DM patients across all age groups and
utilize health records (UK) and claims data (US) from
both private and public insurance plans, providing
broadly representative study samples.
Details on the data available within each of these data
sources for the purpose of evaluating OAD use have been
previously described [18]. At the time of data collection,
CPRD contains electronic medical records of over 15
million UK patients across 684 practices [19], and
THIN contained primary medical records for over 11
million UK patients across over 550 practices [20,21].
CPRD and THIN collect demographic information,
medical diagnoses and surgical procedures (recorded
using Read codes), outpatient laboratory results, and
general practitioner-issued prescriptions [22,23]. Since
some UK practices contribute data to both CPRD and
THIN [24], we excluded overlapping patients from
THIN data to ensure that these patients were not
counted twice. US Medicare is the largest national
health insurance program administered by the US
federal government, serving approximately 47.5 million
people as of 2010 [25]. Medicare is available to US citizens
aged 65 years or older and those under 65 years with
certain disabilities. The HIRDSM is one of the largest
longitudinal commercial health insurance databases in
the US, serving 23.2 million members as of 2010 [26-28].
Both Medicare and the HIRDSM contain demographic
information, inpatient and outpatient medical diagnoses
(recorded using International Classification of Diseases,
Ninth Revision, Clinical Modification diagnosis codes),
surgical procedures (recorded with Current Procedural
Terminology codes), and dispensed medications (recorded
by National Drug Codes). Although codes for ordered
laboratory tests can be identified within Medicare and the
HIRDSM, the results of these tests are not recorded in
Medicare and are only available in a subset of
HIRDSM patients. To avoid the possibility of double-
counting patients concurrently enrolled in both of
these US data sources, we only included HIRDSM data
for persons aged 18–64 years and censored HIRDSM
enrollees at age 65 years.
The study was approved by the University of Pennsylvania
and Rutgers University Institutional Review Boards,
the Quorum Review Institutional Review Board (HIRDSM),
and the Independent Scientific Advisory Committees for
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from the Centers for Medicare and Medicaid Services
(US Medicare).
Study patients
Patients were eligible for study inclusion if they were: 1)
newly prescribed (in the UK) or dispensed (in the US)
either saxagliptin, as a single agent or in combination
with other OADs, or an OAD in a class other than DPP-4
inhibitors (“index drug”); 2) ≥18 years old; and 3) enrolled
in their respective data source for at least 180 days prior
to initiation of their index drug. The rationale for selecting
new initiators of other OADs as the comparator group
was to study patients with diabetes who required initiation
of new OAD therapy. Given that we wished to identify
factors specifically associated with saxagliptin use, we did
not include new initiators of other DPP-4 inhibitors within
the comparator OAD group.
All eligible patients prescribed saxagliptin were included.
Within each data source, a random sample (without
replacement) of up to ten new initiators of non-DPP-4
inhibitor OADs was selected for each saxagliptin initiator.
These patients were matched on age (within 5-year age
groups), sex, and geographic region (i.e., country within
UK data sources; census region within US data sources).
Main study outcome
The main study outcome was a new prescription
(UK data source) or pharmacy claim (US data source) for
either saxagliptin or a non-DPP-4 inhibitor OAD. The
index date was defined as the date of first prescription of
saxagliptin or comparator OAD in the respective data
source.
Determinants of saxagliptin use
The following variables were evaluated as determinants of
use of saxagliptin compared to other OADs: calendar year
of initiation, medical comorbidities, surgical procedures,
and medications of interest (listed in Table 1). In clinical
practice, primary care physicians and endocrinologists
likely select and prescribe oral anti-diabetic drugs
based on consideration of at least many of these factors.
We included a variety of medications and drug classes as
potential determinants of saxagliptin because concerns
for drug-drug interactions or exacerbation of medica-
tion toxicities might influence decisions to prescribe
saxagliptin.
Comorbidities were identified based on the presence
of diagnoses recorded in the 180 days prior to the index
date within US Medicare and HIRDSM, and at any time
prior to the index date within CPRD and THIN. General
practitioners in the UK do not have a financial incentive
to record pre-existing diagnoses at each visit and only
utilizing diagnoses recorded in the 180 days prior tothe index date could lead to incomplete comorbidity
ascertainment within the UK data sources. Within all
data sources, pre-existing microvascular and macrovascular
T2DM complications were determined based on diagnoses
and surgical procedures recorded within 180 days prior to
the index date and categorized according to the Diabetes
Complications Severity Index [29].
Within the UK data sources, we collected the closest
hemoglobin A1c result recorded in the 180 days prior to
the index date. Smoking history and obesity, defined as
body mass index (calculated as height in meters/[body
weight in kg]2) >30 kg/m2, were also extracted from
CPRD and THIN. Within the US data sources, we collected
the number of claims for hemoglobin A1c tests recorded in
the 180 days prior to the index date, since patients with
unmanaged and/or severe T2DM typically have hemoglobin
A1c measured more frequently [30].
Across all data sources, patients were considered
exposed to a particular drug if a prescription or pharmacy
claim for that drug was recorded within 180 days prior to
the index date. Particularly, prior OAD use within the
180 days preceding the index date was determined.
Patients whose prescriptions or claims for their existing
OAD therapy continued for 90 days before and after the
initiation of their index drug were considered to have
“added on” saxagliptin or the comparator OAD to their
current therapy. Patients whose prescriptions or claims
for their existing OAD therapy were recorded 90 days
before, but not after, the initiation of the index drug
were considered to have “switched to” saxagliptin or a
comparator OAD.
Statistical analysis
Baseline characteristics of new initiators of saxagliptin
or other OADs were compared using standardized
differences, of which a value exceeding 0.1 is generally
considered meaningful [31]. For the purpose of these
analyses, standardized difference was calculated as the
difference in mean (or proportion for binary variables)
divided by the standard deviation (pooled standard
deviation for the continuous variables). Conditional logis-
tic regression was used to determine adjusted odds ratios
with 95% confidence intervals of saxagliptin use associ-
ated with demographic variables, comorbidities, and
drug therapies. To explore whether the determinants
of saxagliptin use were different between first-time
OAD initiators and those who were previously treated
with OADs, we re-ran analyses in each database, stratified
by whether patients received prior OAD therapy. Because
the conditional logistic regression is conditioned on the
matched group, initiators who no longer had a matched
comparator in the stratified cohorts were removed
from this analysis. Data were analyzed using SAS 9.4
(SAS Institute Inc., Cary, NC).
Table 1 Demographic characteristics of type 2 diabetes mellitus patients within United Kingdom data sources









(n = 1,962) (n = 19,484) (n = 2,084) (n =19,936)
Mean (SD) age, years† 52.7 (10.6) 52.2 (10.6) 0.01 64.7 (12.9) 64.6 (12.9) 0.01
Male sex† 58.2% 58.2% <0.01 57.7% 57.0% 0.01
UK country†
England 60.4% 60.6% <0.01 63.1% 65.7% 0.05
Northern Ireland 7.1% 7.0% <0.01 5.3% 5.0% 0.01
Scotland 11.4% 11.5% <0.01 12.3% 12.8% 0.01
Wales 21.0% 20.9% <0.01 19.2% 16.5% 0.07
Other OAD initiated at index date
Alpha-glucosidase inhibitors: Acarbose 0% 0.2% - 0% 0.2% -
Biguanide: Metformin 0% 63.1% - 0% 62.1% -
Meglitinides 0% 0.4% - 0% 0.4% -
Nateglinide 0% 0.1% - 0% 0.0% -
Repaglinide 0% 0.3% - 0% 0.3% -
Sulfonylureas 0% 27.9% - 0% 29.1% -
Glibenclamide (Glyburide in US data sources) 0% 0.2% - 0% 0.2% -
Gliclazide 0% 24.9% - 0% 26.1% -
Glimepiride 0% 2.1% - 0% 1.9% -
Glipizide 0% 0.6% - 0% 0.7% -
Tolbutamide 0% 0.1% - 0% 0.2% -
Thiazolidinediones 0% 8.3% - 0% 8.2% -
Pioglitazone 0% 8.1% - 0% 8.0% -
Rosiglitazone 0% 0.2% - 0% 0.2% -
On glucagon-like peptide-1 receptor agonist 3.1% 1.9% 0.08 2.4% 1.9% 0.03
On insulin 5.4% 7.3% 0.08 7.7% 7.2% 0.02
Hemoglobin A1c measurements
Mean (SD) 8.7 (1.6) 8.6 (1.8) 0.06 8.8 (1.6) 8.6 (1.8) 0.08
Hemoglobin A1c >8% 57.6% 39.8% 0.36 56.2% 40.8% 0.31
Mean body mass index (SD) 32.4 (6.5) 31.5 (6.7) 0.14 - - -
Missing values 42.9% 41.4% 0.03 0.7% 2.0% 0.11
Underweight (15–18.5 kg/m2) 0.2% 0.4% 0.03 0.0% 0.4% 0.08
Normal (18.5-24.9 kg/m2) 4.4% 6.7% 0.10 7.9% 11.4% 0.12
Overweight (25.0-29.9 kg/m2) 15.9% 17.8% 0.05 29.0% 31.5% 0.05
Obese (30–60 kg/m2) 36.7% 33.9% 0.06 62.3% 54.7% 0.15
Smoking 36.5% 36.5% <0.01 63.5% 61.0% 0.05
Severity of type 2 diabetes mellitus (prior 180 d)
Cerebrovascular disease 0.5% 0.7% 0.02 0.9% 0.7% 0.02
Coronary artery disease, congestive heart failure,
ventricular tachycardia/fibrillation
1.3% 1.5% 0.01 1.9% 1.5% 0.03
Diabetic coma 0% 0.1% - 0% 0.1% -
Nephropathy 0.3% 0.2% 0.02 0.6% 0.2% 0.06
Neuropathy 0.8% 0.6% 0.02 0.9% 0.6% 0.03
Peripheral vascular disease 1.1% 0.9% 0.02 1.2% 0.9% 0.03
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Table 1 Demographic characteristics of type 2 diabetes mellitus patients within United Kingdom data sources
(Continued)
Retinopathy 5.7% 3.7% 0.09 5.5% 3.5% 0.10
Unspecified additional diabetic complications 0% 0.0% - 0% 0.0% -
Medical comorbidities
Allergic rhinitis/hay fever 8.8% 10.0% 0.04 9.1% 9.4% 0.01
Asthma 16.0% 15.8% <0.01 16.4% 15.9% 0.01
Chronic obstructive pulmonary disease/bronchitis 12.1% 10.0% 0.07 13.1% 10.7% 0.07
Dermatologic disorder
Eczema 17.0% 15.2% 0.05 16.9% 14.2% 0.08
Psoriasis/psoriatic arthritis 6.4% 5.1% 0.06 5.8% 5.3% 0.02
Gastrointestinal disease
Cirrhosis 0.3% 0.4% 0.01 0.2% 0.4% 0.03
Gallbladder disease 6.2% 5.6% 0.02 6.3% 5.9% 0.02
Hemochromatosis 0.1% 0.1% 0.02 0% 0.2% 0.04
Hyperlipidemia 16.0% 12.0% 0.12 15.9% 12.2% 0.11
Hypertension 56.7% 50.9% 0.12 61.0% 56.1% 0.10
Infectious disease
Hepatitis B virus infection 0.3% 0.2% 0.02 0.2% 0.2% 0.01
Hepatitis C virus infection 0% 0.1% - 0% 0.1% -
Malignancy
Hematologic 0.8% 1.0% 0.03 0.9% 1.0% <0.01
Solid organ 23.5% 22.9% 0.02 22.9% 23.9% 0.02
Obesity 17.8% 14.6% 0.09 17.0% 13.4% 0.10
Rheumatoid arthritis 2.7% 2.4% 0.02 1.3% 1.7% 0.03
Medications
Acetaminophen/paracetamol 31.7% 28.7% 0.06 32.0% 30.1% 0.04
Anti-asthmatic agents 18.6% 17.7% 0.02 18.8% 18.1% 0.02
Antibacterials 35.5% 33.9% 0.03 32.1% 30.7% 0.03
Anticonvulsants 8.8% 7.8% 0.04 6.2% 5.1% 0.05
Antifungals 3.0% 2.6% 0.02 2.9% 3.4% 0.03
Antihistamines 7.2% 7.1% <0.01 7.5% 6.9% 0.02
Anti-hyperlipidemic agents 80.6% 58.5% 0.49 81.1% 61.9% 0.43
Antihypertensive agents
Angiotensin-converting enzyme inhibitors 46.5% 36.1% 0.21 46.1% 38.4% 0.16
Angiotensin receptor blockers 19.2% 13.2% 0.16 22.5% 15.0% 0.19
Beta blockers 24.7% 20.7% 0.09 28.0% 23.2% 0.11
Calcium channel blockers 28.2% 23.8% 0.10 29.9% 26.9% 0.07
Loop diuretics 12.4% 11.0% 0.04 17.3% 11.4% 0.17
Other antihypertensive agents 9.2% 6.8% 0.09 10.0% 6.8% 0.11
Thiazide diuretics 19.9% 16.1% 0.10 25.1% 20.8% 0.10
Antivirals 0.7% 0.8% 0.02 0.8% 0.9% 0.02
Non-aspirin non-steroidal anti-inflammatory 13.4% 13.0% 0.01 12.5% 13.0% 0.02
Other antiplatelet/anticoagulant agents
Aspirin 38.3% 29.7% 0.18 42.1% 32.2% 0.21
Clopidogrel 4.9% 3.7% 0.06 5.0% 3.7% 0.06
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Table 1 Demographic characteristics of type 2 diabetes mellitus patients within United Kingdom data sources
(Continued)
Low-molecular-weight heparin 0.2% 0.3% 0.03 0.5% 0.3% 0.02
Warfarin 5.4% 4.9% 0.02 6.9% 5.6% 0.05
Other medications
Allopurinol 3.2% 3.5% 0.02 5.1% 3.7% 0.07
Anti-arrhythmics 3.4% 2.6% 0.05 3.1% 3.0% <0.01
Immune modulators/immunosuppressants 1.2% 1.2% <0.01 1.2% 1.2% 0.01
Nitroglycerin 5.6% 5.1% 0.02 6.3% 4.9% 0.06
Urinary anti-spasmodics 4.3% 3.3% 0.05 4.7% 3.6% 0.06
Psychotropic agents
Antidepressants 22.1% 19.6% 0.06 20.6% 19.6% 0.03
Antipsychotics 4.3% 4.4% 0.01 4.9% 4.8% 0.01
Prior OAD Therapy‡ 93.7% 35.8% 1.53 92.1% 36.8% 1.41
Alpha-glucosidase inhibitors: Acarbose 0.3% 0.1% 0.03 0.2% 0.1% 0.03
Biguanide: Metformin 83.4% 73.7% 0.24 77.7% 73.1% 0.11
Meglitinides 1.1% 0.4% 0.09 1.2% 0.3% 0.10
Nateglinide 0.2% 0.0% 0.04 0.2% 0.1% 0.04
Repaglinide 0.9% 0.3% 0.08 1.0% 0.2% 0.10
Sulfonylureas 47.9% 12.2% 0.84 46.4% 12.8% 0.79
Glibenclamide 0.4% 0.5% 0.01 0.5% 0.6% 0.01
Gliclazide 41.4% 12.6% 0.69 39.3% 13.4% 0.61
Glimepiride 4.5% 1.5% 0.18 4.1% 1.4% 0.17
Glipizide 1.1% 0.7% 0.04 1.7% 0.8% 0.09
Tolbutamide 0.7% 0.1% 0.09 1.1% 0.2% 0.11
Thiazolidinediones 16.6% 5.3% 0.37 17.7% 5.1% 0.40
Pioglitazone 14.1% 3.5% 0.38 15.4% 3.4% 0.42
Rosiglitazone 2.7% 2.1% 0.03 2.5% 2.0% 0.03
Abbreviations: OAD = oral anti-diabetic drug; SD = standard deviation.
*Characteristics are presented as percentages unless otherwise indicated.
†Matching criteria for which a random sample (without replacement) of up to ten new initiators of non-DPP-4 inhibitor OADs were selected for each
saxagliptin initiator.
‡Defined as use of an oral anti-diabetic drug within the 180 days prior to the initiation of the index drug. Denominator adjusted to exclude those on index drug.
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Patient characteristics
UK data sources
Within THIN and CPRD, respectively, we identified,
1,962 and 2,084 new initiators of saxagliptin (Figure 1a
and b) as well as 19,484 and 19,936 matched new initia-
tors of non-DPP-4 inhibitor OADs. The characteristics of
these patients are presented in Table 1. Approximately 6%
of saxagliptin initiators in each UK data source had not
received treatment for T2DM with another OAD within
180 days prior to the index date.
Within both UK data sources, saxagliptin initiators
were more likely to have had prior OAD therapy and
hemoglobin A1c results >8% in the 180 days preceding
the index prescription compared to initiators of other
non-DPP-4 inhibitor OADs. Saxagliptin users also
more frequently had hyperlipidemia, hypertension, andobesity and were more commonly prescribed aspirin,
anti-hyperlipidemic agents, and anti-hypertensive drugs.
Within THIN, diagnoses of retinopathy were more preva-
lent among saxagliptin initiators.
US data sources
During the initial 29 months of saxagliptin availability
within US Medicare, 51,976 new initiators of saxagliptin
and 493,432 matched new initiators of non-DPP-4
inhibitor OADs were identified (Figure 1c). During
the initial 36 months of saxagliptin availability within
the HIRDSM, 8,057 new initiators of saxagliptin and
77,808 matched new initiators of non-DPP-4 inhibitor
OADs were identified (Figure 1d). The characteristics of
these patients are presented in Table 2. Approximately
22% of saxagliptin initiators in US Medicare and
33% of saxagliptin initiators in the HIRDSM had not
Figure 1 Selection of saxagliptin patients. a: Clinical Practice Research Datalink (CPRD). b: The Health Improvement Network (THIN). c: US
Medicare. d: HealthCore Integrated Research DatabaseSM (HIRDSM).
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within 180 days prior to the index date.
Within both US databases, saxagliptin initiators
more frequently received prior OAD therapy and had
higher mean numbers of hemoglobin A1c measure-
ments in the 180 days prior to the index date. Saxa-
gliptin initiators were also more frequently diagnosed
with hyperlipidemia and hypertension and more com-
monly received anti-hyperlipidemic drugs, angiotensin-
converting enzyme inhibitors, and angiotensin receptor
blockers. Within US Medicare, diagnoses of micro-
vascular T2DM complications, including nephropathy
and neuropathy, were more prevalent among saxagliptin
initiators.
Factors associated with saxagliptin use
UK data sources
Factors associated with saxagliptin initiation within
CPRD and THIN are presented in Table 3. Prior OAD
use in the 180 days preceding the index date was
strongly associated with saxagliptin initiation in CPRD
and THIN. Within THIN, diabetic nephropathy and
obesity were also associated with a higher likelihood of
saxagliptin initiation.
After stratifying on prior OAD use within CPRD,
results were similar to those in the primary analysis.
However, prescriptions for antihyperlipidemic agents
and diagnoses of chronic obstructive pulmonary dis-
ease and bronchitis were associated with saxagliptininitiation among patients without prior OAD use
(Table 3).
After stratifying on prior OAD use within THIN,
results were also similar to those in the primary ana-
lysis. However, obesity and diabetic nephropathy
were more strongly associated with saxagliptin initi-
ation among those with prior OAD use. Additionally,
among patients with no prior OAD use, prescrip-
tions for antihyperlipidemics and diagnoses of retin-
opathy were associated with saxagliptin initiation
(Table 3).
US data sources
Factors associated with saxagliptin initiation in US
Medicare and the HIRDSM are presented in Table 4.
Saxagliptin initiation was associated with prior OAD use
and a greater number of hemoglobin A1c measurements
in the 180 days preceding the index date in Medicare and
the HIRDSM. Additionally, within Medicare, saxagliptin
initiators were more likely to receive angiotensin-receptor
blockers.
After stratifying on prior OAD use within US Medicare,
results were similar to those in the primary analysis.
However, use of angiotensin-receptor blockers was
more strongly associated with saxagliptin use among
those without prior OAD use (Table 4).
After stratifying on prior OAD use within the
HIRDSM, results remained similar to those within the
primary analyses (Table 4).
Table 2 Demographic characteristics of type 2 diabetes mellitus patients within United States data sources










(n = 51,976) (n = 493,432) (n =8,057) (n =77,808)
Mean (SD) age, years† 70.4 (11.1) 69.9 (11.0) 0.04 52.9 (8.4) 52.9 (8.4) 0.01
Male sex† 42.1% 42.8% 0.01 60.0% 59.5% 0.01
US census region†
East North Central 12.7% 12.8% <0.01 20.7% 21.2% 0.01
East South Central 10.0% 10.0% <0.01 10.0% 10.1% <0.01
Middle Atlantic 16.0% 15.9% <0.01 9.0% 8.9% <0.01
Mountain 3.1% 3.1% <0.01 1.9% 1.9% <0.01
New England 2.8% 2.8% <0.01 5.7% 5.9% <0.01
Pacific 12.8% 13.1% <0.01 14.6% 14.8% <0.01
South Atlantic 24.1% 24.0% <0.01 30.5% 29.9% 0.01
West North Central 5.2% 5.0% <0.01 5.3% 5.4% <0.01
West South Central 13.2% 13.2% <0.01 2.2% 1.9% 0.02
Other OAD initiated at index date
Alpha-glucosidase inhibitors 0% 0.6% - 0% 0.4% -
Acarbose 0% 0.5% - 0% 0.3% -
Miglitol 0% 0.0% - 0% 0.0% -
Biguanide: Metformin 0% 51.5% - 0% 69.1% -
Meglitinides 0% 2.4% - 0% 0.9% -
Nateglinide 0% 1.0% - 0% 0.4% -
Repaglinide 0% 1.3% - 0% 0.5% -
Sulfonylureas 0% 33.8% - 0% 22.0% -
Chlorpropamide 0% 0.0% - 0% 0.0% -
Glimepiride 0% 11.0% - 0% 8.1% -
Glipizide 0% 14.3% - 0% 8.3% -
Glyburide (glibenclamide in UK data sources) 0% 8.5% - 0% 5.6% -
Tolazamide 0% 0.0% - 0% 0.0% -
Tolbutamide 0% 0.0% - 0% 0.0% -
Thiazolidinediones 0% 11.7% - 0% 7.7% -
Pioglitazone 0% 11.0% - 0% 7.3% -
Rosiglitazone 0% 0.8% - 0% 0.4% -
On glucagon-like peptide-1 receptor agonist 2.1% 1.1% 0.07 3.8% 2.9% 0.05
On insulin 15.9% 14.9% 0.03 9.7% 8.3% 0.05
Mean (SD) number of hemoglobin A1c measures 1.3 (0.9) 0.9 (0.9) 0.51 1.1 (0.8) 0.8 (0.8) 0.50
Severity of type 2 diabetes mellitus (prior 180 d)
Cerebrovascular disease 10.5% 10.6% <0.01 2.4% 2.4% <0.01
Coronary artery disease, congestive heart failure, ventricular
tachycardia/fibrillation
40.8% 38.2% 0.05 11.8% 11.1% 0.02
Metabolic (ketoacidosis, hyperosmolar,coma) 1.3% 1.3% <0.01 0.7% 0.7% <0.01
Nephropathy 20.2% 15.7% 0.11 5.0% 3.6% 0.07
Neuropathy 22.9% 18.1% 0.12 8.3% 6.8% 0.06
Peripheral vascular disease 18.4% 16.6% 0.05 3.9% 3.4% 0.03
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Table 2 Demographic characteristics of type 2 diabetes mellitus patients within United States data sources (Continued)
Retinopathy 13.3% 10.5% 0.09 5.3% 3.9% 0.07
Unspecified additional diabetic complications 7.9% 6.9% 0.04 3.8% 2.7% 0.06
Medical comorbidities
Allergic rhinitis/hay fever 7.1% 5.6% 0.06 5.2% 4.6% 0.03
Asthma 7.7% 7.9% 0.01 3.8% 4.3% 0.02
Chronic obstructive pulmonary disease/bronchitis 12.5% 13.4% 0.03 2.7% 3.0% 0.02
Dermatologic disorders
Eczema 3.5% 3.0% 0.02 2.2% 1.9% 0.02
Psoriasis/psoriatic arthritis 0.9% 0.9% <0.01 0.9% 0.9% 0.01
Gastrointestinal disease
Cirrhosis 0.8% 0.8% <0.01 0.3% 0.4% 0.01
Gallbladder disease 2.2% 2.3% 0.01 1.1% 1.1% <0.01
Hemochromatosis 0.3% 0.2% 0.01 0.2% 0.2% <0.01
Hyperlipidemia 77.1% 66.3% 0.24 62.0% 48.7% 0.27
Hypertension 85.3% 78.1% 0.18 60.9% 50.9% 0.20
Infections
Hepatitis B virus infection 0.2% 0.2% <0.01 0.2% 0.2% 0.01
Hepatitis C virus infection 0.8% 0.9% 0.02 0.5% 0.5% <0.01
Human immunodeficiency virus 0.2% 0.4% 0.02 0.1% 0.2% 0.03
Malignancy
Hematologic 1.3% 1.3% 0.01 0.6% 0.6% 0.01
Solid organ 8.2% 8.6% 0.01 3.3% 3.3% <0.01
Obesity 11.1% 10.7% 0.01 9.3% 9.4% <0.01
Rheumatoid arthritis 2.8% 2.5% 0.02 0.9% 0.9% <0.01
Medications
Acetaminophen/paracetamol 28.1% 26.3% 0.04 20.2% 19.8% 0.01
Anti-asthmatic agents 14.4% 12.5% 0.05 8.3% 7.9% 0.01
Antibacterials 46.3% 40.3% 0.12 38.1% 35.7% 0.05
Anticonvulsants 5.4% 5.6% 0.01 7.2% 7.5% 0.01
Antifungals 10.1% 8.1% 0.07 6.8% 5.7% 0.05
Antihistamines 11.8% 9.4% 0.08 6.4% 5.7% 0.03
Anti-hyperlipidemic agents 69.2% 52.8% 0.34 53.5% 38.6%) 0.30
Antihypertensive agents
Angiotensin-converting enzyme inhibitors 43.1% 37.2% 0.12 35.8% 28.0% 0.17
Angiotensin receptor blockers 28.5% 18.0% 0.25 20.1% 14.1% 0.16
Beta blockers 44.0% 36.1% 0.16 21.2% 18.4% 0.07
Calcium channel blockers 31.7% 26.3% 0.12 16.0% 13.9% 0.06
Loop diuretics 23.1% 18.1% 0.12 5.1% 4.7% 0.02
Other antihypertensive agents 11.9% 9.0% 0.10 4.8% 3.9% 0.04
Thiazide diuretics 21.7% 15.6% 0.16 18.2% 15.0% 0.09
Antivirals 2.3% 2.0% 0.02 1.9% 2.5% 0.04
Non-aspirin non-steroidal anti-inflammatory 17.4% 14.7% 0.08 13.9% 12.9% 0.03
Other antiplatelet/anticoagulant agents
Aspirin 0.8% 0.6% 0.02 0.1% 0.1% 0.01
Clopidogrel 13.7% 10.4% 0.10 4.0% 3.6% 0.02
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Table 2 Demographic characteristics of type 2 diabetes mellitus patients within United States data sources (Continued)
Low-molecular-weight heparin 0.5% 0.7% 0.02 0.4% 0.4% 0.01
Warfarin 7.4% 7.0% 0.02 2.1% 1.7% 0.03
Other medications
Allopurinol 5.4% 4.1% 0.06 2.5% 2.4% <0.01
Anti-arrhythmics 13.6% 12.2% 0.04 4.7% 4.6% 0.01
Immune modulators/immunosuppressants 4.5% 4.1% 0.02 2.2% 2.4% 0.01
Nitroglycerin 4.6% 3.8% 0.04 1.3% 1.3% <0.01
Urinary anti-spasmodics 5.4% 4.5% 0.04 0.9% 1.2% 0.03
Psychotropic agents
Antidepressants 27.4% 25.3% 0.05 19.1% 18.9% <0.01
Antipsychotics 7.5% 7.8% 0.01 2.1% 2.3% 0.01
Prior OAD Therapy‡ 77.6% 36.1% 0.92 66.7% 23.2% 0.97
Alpha-glucosidase inhibitors 0.8% 0.3% 0.08 0.4% 0.1% 0.05
Acarbose 0.7% 0.2% 0.07 0.4% 0.1% 0.05
Miglitol 0.1% 0.0% 0.03 0.0% 0.0% 0.02
Biguanide: Metformin 51.4% 37.4% 0.29 51.9% 42.6% 0.19
Meglitinides 3.0% 1.1% 0.13 1.4% 0.4% 0.10
Nateglinide 1.5% 0.5% 0.10 0.8% 0.2% 0.08
Repaglinide 1.6% 0.7% 0.09 0.7% 0.2% 0.07
Sulfonylureas 42.5% 16.8% 0.59 28.0% 8.7% 0.51
Chlorpropamide 0.0% 0.0% <0.01 0.0% 0.0% 0.01
Glimepiride 16.5% 5.3% 0.37 12.3% 3.2% 0.34
Glipizide 17.7% 8.8% 0.27 11.0% 4.3% 0.26
Glyburide 9.5% 5.2% 0.16 5.2% 2.0% 0.17
Tolazamide 0.0% 0.0% 0.01 0% 0% -
Tolbutamide 0.0% 0.0% <0.01 0% 0% -
Thiazolidinediones 24.2% 8.4% 0.44 15.0% 5.5% 0.32
Pioglitazone 21.4% 7.3% 0.41 13.6% 5.0% 0.30
Rosiglitazone 3.2% 1.9% 0.08 1.5% 0.9% 0.05
Abbreviations: OAD = oral anti-diabetic drug; SD = standard deviation.
*Characteristics are presented as percentages unless otherwise indicated.
†Matching criteria for which a random sample (without replacement) of up to ten new initiators of non-DPP-4 inhibitor OADs were selected for each
saxagliptin initiator.
‡Defined as use of an oral anti-diabetic drug within the 180 days prior to the initiation of the index drug. Denominator adjusted to exclude those on index drug.
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Drug utilization studies can reveal how medications are
administered in clinical practice, identify determinants
of drug use, ensure robust prescribing practices [32],
and establish topics for further study of drug effective-
ness and safety [14]. This study found that across two
UK and two US data sources, prior OAD use, hyperten-
sion, and hyperlipidemia were associated with initiation of
saxagliptin rather than other OADs. Saxagliptin initiation
was also associated with hemoglobin A1c results >8%
within the UK data sources, and a greater number of
hemoglobin A1c measurements in the US data sources.
Interestingly, saxagliptin was the first OAD utilized
for approximately 6% of patients within the UK datasources, 22% of patients within US Medicare, and
33% of patients within the HIRDSM. Results from US
Medicare and THIN suggest that saxagliptin may be a pre-
ferred treatment in patients with more severe (advanced)
T2DM, as evidenced by increased diagnoses for micro-
vascular complications. According to these findings,
patients prescribed saxagliptin had higher prevalence
of comorbid conditions, poor glycemic control, inadequate
response to prior OAD therapy, or contraindications to
OADs in other classes.
Stratifying our analyses on prior OAD use demonstrated
that some determinants were more strongly associated
with saxagliptin initiation among patients who had
not received prior OAD therapy, particularly within
Table 3 Determinants of saxagliptin use among type 2 diabetes mellitus patients within United Kingdom data sources
Adjusted odds ratio (95% confidence interval)*









(n = 21,446) (n = 8,332) (n = 890) (n = 22,020) (n = 8,621) (n = 1,137)
Hemoglobin A1c >8% 1.26 (1.13-1.39) 1.21 (1.08-1.35) 1.66 (1.05-2.63) 1.17 (1.06-1.30) 1.12 (1.01-1.25) 1.39 (0.95-2.03)
Overweight vs. < 25 kg/m2 0.91 (0.78-1.07) 0.87 (0.73-1.03) 1.32 (0.67-2.62) 1.38 (1.15-1.67) 1.44 (1.17-1.76) 0.95 (0.48-1.87)
Obese vs. < 25 kg/m2 1.13 (0.99-1.29) 1.12 (0.97-1.30) 1.61 (0.88-2.94) 1.74 (1.45-2.09) 1.83 (1.50-2.22) 0.86 (0.44-1.68)
Smoking 0.93 (0.81-1.06) 0.94 (0.81-1.08) 0.73 (0.43-1.26) 1.03 (0.93-1.15) 1.03 (0.92-1.16) 0.86 (0.57-1.30)
Severity of type 2 diabetes mellitus
Cardiovascular 1.05 (0.90-1.23) 1.03 (0.87-1.22) 1.49 (0.74-3.00) 0.97 (0.84-1.13) 1.01 (0.86-1.18) 0.74 (0.43-1.28)
Cerebrovascular 0.79 (0.64-0.98) 0.80 (0.64-1.01) 0.52 (0.20-1.38) 0.87 (0.72-1.05) 0.89 (0.72-1.09) 0.65 (0.31-1.40)
Nephropathy 1.08 (0.78-1.50) 1.05 (0.74-1.50) 1.40 (0.41-4.80) 1.75 (1.33-2.30) 1.77 (1.32-2.39) 1.79 (0.61-5.23)
Peripheral vascular disease 0.88 (0.73-1.07) 0.90 (0.74-1.10) 0.54 (0.21-1.35) 0.83 (0.69-1.00) 0.83 (0.68-1.01) 1.32 (0.65-2.68)
Retinopathy 1.11 (0.98-1.25) 1.06 (0.93-1.20) 2.25 (1.27-3.99) 1.20 (1.06-1.35) 1.14 (1.00-1.29) 2.63 (1.64-4.22)
Diagnoses
Allergic rhinitis/hay fever 0.83 (0.69-1.00) 0.88 (0.73-1.07) 0.36 (0.13-0.97) 0.92 (0.77-1.11) 0.99 (0.82-1.21) 0.52 (0.25-1.07)
Asthma 0.99 (0.83-1.17) 0.96 (0.80-1.15) 1.35 (0.63-2.86) 0.99 (0.84-1.17) 0.96 (0.80-1.15) 1.44 (0.79-2.64)
Chronic obstructive pulmonary disease 1.23 (1.03-1.46) 1.18 (0.98-1.42) 2.64 (1.34-5.18) 1.21 (1.03-1.43) 1.21 (1.01-1.44) 1.48 (0.79-2.77)
Collagen vascular disease/autoimmune disorders 0.96 (0.82-1.13) 0.94 (0.79-1.11) 1.40 (0.64-3.07) 1.01 (0.86-1.17) 1.03 (0.88-1.22) 1.11 (0.59-2.12)
Dermatologic disorders 1.08 (0.96-1.22) 1.12 (0.99-1.27) 0.50 (0.28-0.89) 1.10 (0.98-1.24) 1.14 (1.00-1.29) 0.97 (0.62-1.52)
Hyperlipidemia 1.19 (1.03-1.37) 1.14 (0.98-1.33) 2.08 (1.14-3.81) 1.21 (1.05-1.39) 1.18 (1.02-1.37) 1.04 (0.59-1.83)
Hypertension 0.86 (0.75-0.98) 0.83 (0.73-0.96) 1.14 (0.67-1.93) 0.88 (0.78-1.00) 0.86 (0.75-0.99) 1.39 (0.87-2.22)
Infectious diseases 1.16 (1.01-1.33) 1.14 (0.99-1.32) 1.63 (0.97-2.76) 1.10 (0.96-1.25) 1.08 (0.94-1.24) 1.30 (0.79-2.13)
Malignancy 0.98 (0.87-1.11) 0.95 (0.84-1.08) 1.78 (1.08-2.95) 0.95 (0.85-1.07) 0.96 (0.84-1.09) 0.83 (0.53-1.29)
Obesity 1.07 (0.93-1.23) 0.99 (0.85-1.15) 1.47 (0.83-2.60) 1.00 (0.87-1.16) 0.96 (0.83-1.13) 1.76 (1.03-3.02)
Other diseases 1.08 (0.94-1.25) 1.08 (0.93-1.26) 0.77 (0.40-1.46) 1.12 (0.97-1.28) 1.06 (0.92-1.23) 1.31 (0.78-2.19)
Drugs
Acetaminophen/paracetamol 0.95 (0.84-1.07) 0.96 (0.84-1.09) 0.80 (0.44-1.46) 0.92 (0.82-1.03) 0.88 (0.78-1.00) 1.18 (0.74-1.87)
Anti-asthmatic agents 0.96 (0.81-1.13) 1.03 (0.86-1.23) 0.50 (0.23-1.07) 0.92 (0.79-1.09) 0.96 (0.81-1.14) 0.78 (0.43-1.44)
Antibacterial agents 1.03 (0.92-1.16) 1.00 (0.89-1.13) 1.36 (0.82-2.26) 0.99 (0.88-1.11) 0.98 (0.87-1.10) 1.08 (0.69-1.69)
Anticonvulsants 1.16 (0.96-1.40) 1.19 (0.98-1.46) 0.87 (0.32-2.37) 1.07 (0.86-1.33) 1.05 (0.83-1.33) 0.95 (0.39-2.35)
Antihistamines 0.93 (0.76-1.14) 0.91 (0.73-1.12) 1.57 (0.61-4.04) 1.01 (0.83-1.23) 0.98 (0.79-1.22) 1.35 (0.65-2.77)
Antihyperlipidemic agents 1.33 (1.16-1.52) 1.21 (1.04-1.39) 2.79 (1.60-4.85) 1.32 (1.15-1.51) 1.19 (1.03-1.38) 2.41 (1.50-3.88)
Antihypertensive agents
Angiotensin-converting enzyme inhibitors 1.11 (0.98-1.26) 1.12 (0.99-1.28) 0.80 (0.44-1.47) 1.00 (0.88-1.12) 0.98 (0.86-1.11) 0.88 (0.55-1.41)
Angiotensin receptor blockers 1.35 (1.16-1.57) 1.36 (1.16-1.60) 1.34 (0.65-2.75) 1.32 (1.14-1.52) 1.29 (1.11-1.51) 1.46 (0.83-2.58)
Beta blockers 1.04 (0.90-1.19) 1.03 (0.89-1.18) 1.46 (0.78-2.72) 1.09 (0.96-1.24) 1.05 (0.92-1.21) 1.49 (0.90-2.45)
Calcium channel blockers 1.00 (0.88-1.13) 1.04 (0.91-1.19) 0.29 (0.15-0.58) 0.94 (0.84-1.06) 0.99 (0.88-1.13) 0.51 (0.31-0.86)
Loop diuretics 0.95 (0.80-1.12) 0.91 (0.76-1.09) 1.00 (0.46-2.19) 1.40 (1.20-1.63) 1.31 (1.11-1.55) 1.94 (1.07-3.52)
Other antihypertensive agents 1.12 (0.97-1.29) 0.98 (0.81-1.19) 2.03 (0.82-5.03) 1.18 (1.02-1.36) 0.91 (0.74-1.12) 1.73 (0.76-3.95)
Thiazide diuretics 1.01 (0.84-1.22) 1.18 (1.02-1.37) 0.39 (0.17-0.94) 0.97 (0.80-1.18) 1.27 (1.10-1.48) 0.54 (0.28-1.02)
Anti-infective agents 0.97 (0.74-1.28) 1.00 (0.75-1.34) 0.59 (0.13-2.64) 0.78 (0.60-1.02) 0.72 (0.54-0.95) 0.80 (0.29-2.26)
Antiplatelet/anticoagulant agents 0.91 (0.81-1.03) 0.90 (0.79-1.02) 1.16 (0.65-2.07) 1.05 (0.93-1.18) 1.01 (0.89-1.14) 1.53 (0.94-2.50)
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Table 3 Determinants of saxagliptin use among type 2 diabetes mellitus patients within United Kingdom data sources
(Continued)
Non-steroidal anti-inflammatory agents 0.98 (0.84-1.14) 0.90 (0.79-1.02) 0.71 (0.30-1.69) 0.98 (0.84-1.15) 1.05 (0.89-1.24) 0.48 (0.24-0.96)
Other medications 1.03 (0.89-1.19) 1.03 (0.89-1.20) 0.63 (0.31-1.29) 1.09 (0.95-1.25) 1.12 (0.97-1.30) 0.79 (0.44-1.41)
Psychotropic agents 0.94 (0.83-1.07) 0.99 (0.87-1.13) 0.51 (0.25-1.05) 0.95 (0.83-1.07) 0.97 (0.85-1.11) 0.58 (0.34-1.00)
Abbreviations: OAD = oral anti-diabetic drug.
*Odds ratios adjusted for all other variables in this table.
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that within THIN, obesity and diabetic nephropathy
were more strongly associated with saxagliptin initiation
among those with prior OAD use. However, stratifying
on prior OAD use reduced the overall sample sizes within
each stratum, particularly for patients without prior
OAD use. As a result, these findings should be interpreted
with caution.
These findings contribute to a growing body of research
evaluating the characteristics of patients prescribed DPP-4
inhibitors. In three studies within the Ingenix (now
Optum) administrative claims database [33-35], patients
treated with sitagliptin, another DPP-4 inhibitor, were
more likely to have medical comorbidities (i.e., cardio-
vascular disease, chronic kidney disease, hypertension,
lipid disorders, and neuropathy) and were more fre-
quently prescribed cardiovascular medications and
insulin. In two additional studies within the General
Electric Healthcare’s Clinical Data Services electronic
medical records database, patients prescribed sitagliptin
were older and had a higher prevalence of preexisting
comorbid conditions than patients prescribed other
OAD therapies [36]. Patients prescribed sitagliptin
were also more likely to have baseline microvascular
and macrovascular complications of T2DM than patients
receiving exenatide [37]. Our results expand under-
standing of the DPP-4 drug class by providing new
data on determinants associated with saxagliptin initi-
ation and including large samples of T2DM patients
within the US and UK.
The observation that saxagliptin was prescribed to a
large proportion of T2DM patients without prior OAD
use in the US data sources (22% within US Medicare;
33% within HIRDSM) compared to the UK data sources
(6%) is surprising given current guidelines recommending
use of metformin as first-line OAD therapy [38]. A recent
study utilizing the IMS Health Vector One National and
Total Patient Tracker databases, a compilation of large
commercial outpatient prescription and patient databases
in the US, similarly found that 28% of non-insulin
OAD users were not prescribed metformin and that
DPP-4 inhibitors were the most commonly prescribed
new drug class of agents [39]. The reasons why saxa-
gliptin was more commonly prescribed as initial OAD
treatment among T2DM patients within the US datasources remain unclear. Decreased metformin use may
be due, in part, to contraindications to the medication
(e.g. renal insufficiency, active liver disease) [40-45].
Further studies are needed to evaluate the reasons for this
deviation from recommended prescribing practices.
Since baseline characteristics of patients with T2DM
have been shown to influence the efficacy of anti-
diabetic therapy [46,47], it will be important to evalu-
ate the determinants of saxagliptin use identified in
this study as effect modifiers and confounders in future
comparative effectiveness and safety studies. Our re-
sults also provide valuable information on variables
that should be considered for inclusion within pro-
pensity score analyses of saxagliptin use for future
pharmacoepidemiologic studies evaluating the compara-
tive effectiveness and safety of saxagliptin compared to
other OADs [18].
A particular strength of our analysis was the inclusion
of data from US Medicare. Prior studies that evaluated
the characteristics of OAD initiators within the US
[33-35,37], but did not include Medicare coverage, likely
underrepresented T2DM patients over the age of 65
and may have incompletely captured claims among
patients also co-enrolled in Medicare. By examining
initiators of saxagliptin and other non-DPP-4 inhibitor
OADs within four data sources (including US Medicare)
and across two continents, our analyses ensured ad-
equate capture and representation of elderly T2DM
patients.
Our study has several potential limitations. First, we
were unable to determine the duration of T2DM due to
the use of administrative data (US data sources) and
incomplete electronic health data from patients who
may have switched practices (UK data sources). Second,
actual exposure to saxagliptin and other OADs cannot
be confirmed. However, minimal misclassification of
medication use is expected since prescribing records
within the UK data sources and pharmacy claims
within the US data sources were used to determine
drug exposure. Additionally, all relevant diagnosis and
procedure codes were included and reviewed by clinical
and pharmacoepidemiology experts to minimize mis-
classification of medical comorbidities examined as
determinants of saxagliptin use. Third, some potentially
important variables, including alcohol and illicit drug use,
Table 4 Determinants of saxagliptin use among type 2 diabetes mellitus patients within United States data sources
Adjusted odds ratio (95% confidence interval)*









(n = 545,408) (n = 177,791) (n = 82,840) (n = 85,865) (n = 17,177) (n = 22,803)
Number of hemoglobin A1c measurements
1 vs. 0 measured 2.10 (2.04-2.16) 2.09 (2.02-2.16) 2.02 (1.91-2.12) 1.67 (1.56-1.78) 1.40 (1.27-1.54) 1.96 (1.77-2.17)
2+ vs. 0 measured 2.93 (2.85-3.01) 2.87 (2.77-2.97) 2.95 (2.78-3.12) 2.33 (2.16-2.51) 1.91 (1.72-2.12) 1.96 (1.77-2.17)
Severity of type 2 diabetes mellitus
Cardiovascular 0.95 (0.93-0.97) 0.95 (0.93-0.98) 0.95 (0.90-1.00) 0.96 (0.88-1.05) 0.97 (0.86-1.10) 1.00 (0.76-1.32)
Cerebrovascular 0.90 (0.88-0.93) 0.92 (0.88-0.95) 0.87 (0.82-0.94) 0.92 (0.78-1.09) 0.93 (0.74-1.17) 0.90 (0.77-1.06)
Metabolic (ketoacidosis, hyperosmolar, coma) 0.95 (0.87-1.03) 0.91 (0.82-1.01) 1.06 (0.89-1.27) - - -
Nephropathy 1.12 (1.09-1.15) 1.08 (1.05-1.12) 1.25 (1.18-1.32) 1.04 (0.93-1.18) 0.87 (0.75-1.02) 1.40 (1.14-1.72)
Neuropathy 1.11 (1.08-1.14) 1.08 (1.05-1.11) 1.22 (1.15-1.28) 1.01 (0.92-1.11) 1.05 (0.92-1.19) 1.03 (0.87-1.22)
Peripheral vascular disease 0.97 (0.94-1.00) 0.97 (0.94-1.01) 0.96 (0.91-1.02) 1.06 (0.92-1.21) 0.92 (0.77-1.11) 1.30 (1.03-1.63)
Retinopathy 1.03 (1.00-1.06) 1.01 (0.97-1.04) 1.09 (1.02-1.16) 1.02 (0.91-1.14) 0.95 (0.82-1.10) 1.11 (0.90-1.37)
Unspecified additional diabetic complications† 0.96 (0.92-0.99) 0.91 (0.82-1.01) 1.12 (1.04-1.22) 1.01 (0.89-1.14) 0.98 (0.83-1.16) 1.17 (0.93-1.47)
Diagnoses
Allergic rhinitis/hay fever 1.16 (1.12-1.21) 1.19 (1.13-1.25) 1.14 (1.05-1.23) 1.12 (1.00-1.26) 1.29 (1.09-1.52) 0.95 (0.78-1.15)
Asthma 0.91 (0.87-0.94) 0.89 (0.85-0.94) 0.94 (0.87-1.02) 0.83 (0.72-0.95) 0.92 (0.76-1.13) 0.80 (0.63-1.02)
Chronic obstructive pulmonary disease 0.92 (0.89-0.95) 0.92 (0.88-0.95) 0.89 (0.83-0.95) 0.93 (0.79-1.08) 0.88 (0.70-1.09) 0.93 (0.72-1.21)
Collagen vascular disease/ autoimmune disorders 1.01 (0.95-1.08) 1.05 (0.97-1.14) 0.93 (0.82-1.06) 0.90 (0.79-1.03) 0.94 (0.79-1.12) 0.82 (0.66-1.03)
Rheumatoid arthritis‡ 1.10 (1.03-1.16) 1.08 (1.00-1.17) 1.17 (1.04-1.32) - - -
Spondyloarthritis‡ 1.04 (1.00-1.09) 1.05 (1.00-1.10) 1.03 (0.95-1.12) - - -
Dermatologic disorders 1.04 (0.99-1.10) 1.02 (0.96-1.09) 1.08 (0.98-1.20) 1.07 (0.93-1.23) 1.10 (0.90-1.34) 1.14 (0.90-1.44)
Psoriasis‡ 0.97 (0.88-1.08) 0.99 (0.87-1.12) 0.86 (0.70-1.06) - - -
Hyperlipidemia 1.11 (1.08-1.14) 1.11 (1.08-1.15) 1.11 (1.05-1.17) 1.17 (1.10-1.24) 1.17 (1.08-1.27) 1.11 (1.01-1.22)
Hypertension 1.00 (0.97-1.03) 1.01 (0.97-1.04) 0.99 (0.93-1.05) 1.13 (1.07-1.20) 1.17 (1.08-1.27) 1.18 (1.07-1.31)
Infectious diseases 0.86 (0.79-0.94) 0.88 (0.79-0.99) 0.85 (0.71-1.02) 0.89 (0.79-1.01) 1.17 (1.08-1.27) 0.95 (0.78-1.16)
Cellulitis‡ 0.92 (0.88-0.95) 0.91 (0.87-0.95) 0.92 (0.85-1.00) - - -
Malignancy 0.93 (0.90-0.97) 0.95 (0.91-0.99) 0.89 (0.83-0.96) 1.02 (0.90-1.17) 1.17 (1.08-1.27) 1.03 (0.83-1.27)
Obesity 0.94 (0.91-0.97) 0.96 (0.92-0.99) 0.90 (0.84-0.97) 0.88 (0.81-0.96) 0.95 (0.84-1.07) 0.76 (0.65-0.88)
Other diseases - - - 0.92 (0.77-1.09) 0.94 (0.74-1.20) 0.93 (0.69-1.24)
Alcohol diseases‡ 0.68 (0.61-0.76) 0.71 (0.62-0.81) 0.90 (0.84-0.97) - - -
Gastrointestinal diseases‡ 1.01 (0.95-1.06) 0.98 (0.91-1.05) 1.07 (0.95-1.20) - - -
Neurological diseases‡ 0.76 (0.63-0.93) 0.86 (0.68-1.08) 0.53 (0.35-0.82) - - -
Drugs
Acetaminophen/paracetamol 0.97 (0.94-0.99) 0.97 (0.94-1.00) 0.96 (0.91-1.01) 0.97 (0.91-1.04) 1.02 (0.93-1.12) 0.87 (0.78-0.98)
Anti-asthmatic agents 1.08 (1.05-1.12) 1.09 (1.05-1.14) 1.08 (1.01-1.16) 1.02 (0.93-1.13) 1.02 (0.88-1.17) 1.06 (0.89-1.25)
Antibacterial agents 1.08 (1.06-1.10) 1.08 (1.05-1.11) 1.08 (1.03-1.13) 1.07 (1.01-1.13) 1.12 (1.04-1.21) 0.95 (0.87-1.04)
Anticonvulsants 0.89 (0.85-0.93) 0.91 (0.87-0.96) 0.81 (0.74-0.90) 0.96 (0.87-1.06) 1.01 (0.88-1.16) 0.89 (0.75-1.07)
Antihistamines 1.10 (1.07-1.14) 1.10 (1.06-1.15) 1.09 (1.01-1.17) 1.05 (0.94-1.16) 1.05 (0.91-1.22) 1.11 (0.93-1.32)
Antihyperlipidemic agents 1.22 (1.19-1.24) 1.15 (1.12-1.19) 1.35 (1.29-1.41) 1.13 (1.07-1.19) 1.11 (1.03-1.20) 1.16 (1.06-1.28)
Antihypertensive agents
Angiotensin-converting enzyme inhibitors 0.98 (0.96-1.01) 0.96 (0.94-0.99) 1.00 (0.96-1.05) 0.97 (0.91-1.02) 0.92 (0.85-1.00) 1.01 (0.90-1.12)
Angiotensin receptor blockers 1.39 (1.36-1.43) 1.32 (1.28-1.36) 1.59 (1.51-1.68) 1.22 (1.13-1.31) 1.07 (0.97-1.19) 1.44 (1.26-1.65)
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Table 4 Determinants of saxagliptin use among type 2 diabetes mellitus patients within United States data sources
(Continued)
Beta blockers 1.04 (1.02-1.06) 1.05 (1.02-1.08) 1.02 (0.98-1.07) 0.99 (0.93-1.06) 1.10 (1.00-1.20) 0.86 (0.76-0.97)
Calcium channel blockers 1.02 (0.99-1.04) 1.01 (0.98-1.04) 1.02 (0.97-1.07) 0.97 (0.90-1.04) 1.04 (0.94-1.14) 0.86 (0.76-0.99)
Loop diuretics 1.10 (1.07-1.13) 1.09 (1.05-1.12) 1.13 (1.07-1.20) 0.94 (0.83-1.06) 0.92 (0.79-1.08) 0.99 (0.80-1.22)
Other antihypertensive agents 1.11 (1.07-1.14) 1.11 (1.07-1.15) 1.09 (1.02-1.17) 1.06 (0.94-1.20) 1.05 (0.96-1.16) 0.99 (0.79-1.24)
Thiazidediuretics 1.14 (1.11-1.17) 1.14 (1.11-1.18) 1.14 (1.08-1.21) 0.99 (0.93-1.07) 1.05 (0.96-1.16) 0.83 (0.73-0.95)
Anti-infective agents - - - 1.04 (0.95-1.14) 1.00 (0.88-1.14) 1.01 (0.86-1.18)
Antifungals‡ 1.10 (1.06-1.14) 1.06 (1.02-1.10) 1.21 (1.13-1.30) - - -
Antivirals‡ 1.09 (1.02-1.16) 1.10 (1.02-1.19) 1.07 (0.93-1.23) - - -
Antiplatelet/anticoagulant agents 0.94 (0.86-1.02) 0.97 (0.87-1.07) 0.91 (0.75-1.10) 0.98 (0.88-1.10) 0.98 (0.84-1.13) 1.07 (0.87-1.32)
Clopidogrel† 1.13 (1.10-1.17) 1.12 (1.08-1.16) 1.18 (1.11-1.26) - - -
Warfarin† 0.96 (0.92-0.99) 0.99 (0.94-1.04) 0.85 (0.78-0.93) - - -
Non-steroidal anti-inflammatory agents 1.06 (1.03-1.09) 1.05 (1.02-1.09) 1.09 (1.03-1.15) 1.02 (0.95-1.10) 1.05 (0.94-1.16) 0.99 (0.87-1.12)
Other medications 1.06 (1.01-1.12) 1.08 (1.01-1.15) 1.08 (0.96-1.22) 0.88 (0.81-0.96) 0.83 (0.75-0.93) 0.99 (0.85-1.14)
Allopurinol‡ 1.05 (1.01-1.10) 1.06 (1.00-1.11) 1.07 (0.97-1.18) - - -
Anti-arrhythmics‡ 0.99 (0.96-1.02) 0.99 (0.95-1.02) 1.00 (0.94-1.08) - - -
Immune modulators/ suppressants‡ 1.05 (1.00-1.10) 1.01 (0.95-1.07) 1.16 (1.04-1.28) - - -
Nitroglycerin‡ 0.98 (0.94-1.03) 0.97 (0.92-1.03) 1.01 (0.92-1.13) - - -
Urinary anti-spasmodics‡ 1.03 (0.98-1.07) 1.03 (0.98-1.09) 1.05 (0.96-1.16) - - -
Psychotropic agents 0.93 (0.91-0.95) 0.92 (0.89-0.94) 0.92 (0.87-0.96) 0.94 (0.88-1.00) 0.95 (0.87-1.04) 0.87 (0.77-0.97)
Abbreviations: OAD = oral anti-diabetic drug.
*Odds ratios adjusted for all other variables in this table.
†For HIRDSM, due to low prevalence, metabolic complications are included in the analyses of unspecified additional diabetic complications.
‡Medications and diseases were evaluated separately within US Medicare because of the large sample size within this data source.
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scription drug use, were not recorded within the data
sources. Finally, our results may not be generalizable
to all settings. However, our analyses have expanded
the populations to which these findings can be gener-
alized by examining results from four different data
sources within the US and UK [48], which contain
claims and medical records data from both private
and public health insurance plans.Conclusion
In summary, this study found that saxagliptin initiation
was more common in patients with prior complications
associated with T2DM, prior OAD use, and diagnoses
and receipt of treatment for hyperlipidemia and hyper-
tension. These variables should be considered in future
studies evaluating the comparative safety and effectiveness
of saxagliptin and other OADs.Abbreviations
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mellitus; THIN: The Health Improvement Network; UK: United Kingdom;
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